Zobrazeno 1 - 10
of 186
pro vyhledávání: '"William M. Sikov"'
Autor:
Maysa M. Abu-Khalaf, K. Alex Hodge, Christos Hatzis, Elisa Baldelli, Emna El Gazzah, Frances Valdes, William M. Sikov, Monica M. Mita, Neelima Denduluri, Rita Murphy, Daniel Zelterman, Lance Liotta, Bryant Dunetz, Rick Dunetz, Emanuel F. Petricoin, Mariaelena Pierobon
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-12 (2023)
Abstract Endocrine therapy (ET) in combination with CDK4/6 inhibition is routinely used as first-line treatment for HR+/HER2− metastatic breast cancer (MBC) patients. However, 30–40% of patients quickly develop disease progression. In this open-l
Externí odkaz:
https://doaj.org/article/c34fa79216b44a448f600ad8e158ac17
Autor:
Otto Metzger-Filho, Katharine Collier, Sarah Asad, Peter J. Ansell, Mark Watson, Junu Bae, Mathew Cherian, Joyce O’Shaughnessy, Michael Untch, Hope S. Rugo, Jens B. Huober, Mehra Golshan, William M. Sikov, Gunter von Minckwitz, Priya Rastogi, Lang Li, Lijun Cheng, David Maag, Norman Wolmark, Carsten Denkert, W. Fraser Symmans, Charles E. Geyer, Sibylle Loibl, Daniel G. Stover
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-6 (2021)
Abstract In the BrighTNess trial, carboplatin added to neoadjuvant chemotherapy (NAC) was associated with increased pathologic complete response (pCR) rates in patients with stage II/III triple-negative breast cancer (TNBC). In this matched cohort st
Externí odkaz:
https://doaj.org/article/c6af5c9ea1394c7ab85bf5141ac651b6
Autor:
Karen L Smith, Fengmin Zhao, Ingrid A Mayer, Amye J Tevaarwerk, Sofia F Garcia, Carlos L Arteaga, William F Symmans, Ben H Park, Brian L Burnette, Della F Makower, Margaret Block, Kimberly A Morley, Chirag R Jani, Craig Mescher, Shabana J Dewani, Ursa Brown-Glaberman, Lisa E Flaum, Erica L Mayer, William M Sikov, Eve T Rodler, Angela M DeMichele, Joseph A Sparano, Antonio C Wolff, Kathy D Miller, Lynne I Wagner
Publikováno v:
Cancer Research. 82:P4-10
Background: Understanding health-related quality of life (HRQOL), including side effects, is critical to guide supportive care during chemotherapy. The EA1131 trial demonstrated that Platinum (Plat) was unlikely to improve outcomes compared to capeci
Autor:
Jonathan H. Shepherd, Karla Ballman, Mei-Yin C. Polley, Jordan D. Campbell, Cheng Fan, Sara Selitsky, Aranzazu Fernandez-Martinez, Joel S. Parker, Katherine A. Hoadley, Zhiyuan Hu, Yan Li, Matthew G. Soloway, Patricia A. Spears, Baljit Singh, Sara M. Tolaney, George Somlo, Elisa R. Port, Cynthia Ma, Charles Kuzma, Eleftherios Mamounas, Mehra Golshan, Jennifer R. Bellon, Deborah Collyar, Olwen M. Hahn, Clifford A. Hudis, Eric P. Winer, Ann Partridge, Terry Hyslop, Lisa A. Carey, Charles M. Perou, William M. Sikov
Publikováno v:
Journal of Clinical Oncology. 40:1323-1334
PURPOSE CALGB 40603 ( NCT00861705 ), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin and cyclophosphamide significantly increased the pathologic complete respon
Autor:
David A Edmondson, Sonali V Pandya, Marlene Cutitar, Ashley Stuckey, Rochelle Strenger, Don S. Dizon, Sabrina M Witherby, Bachir J. Sakr, William M. Sikov, Mary Anne Fenton, Jennifer Gass, Mary L Lopresti, Robert D. Legare, Theresa A. Graves, Christine M Emmick, Adam J. Olszewski, Jessica J Bian
Publikováno v:
Cancer Research. 80:P2-16
In H+BC, neoadjuvant chemotherapy (NACT) with dual HER2-targeted therapy achieves high pathologic complete response (pCR) rates, but the most common anthracycline-free regimen, every 3-week docetaxel and Cb with T and P (TCHP), causes significant hem
Autor:
Jessica L Lyon, Pulluri Bhargavi, Marie E. Wood, William M. Sikov, Pouyan N Changizzadeh, Bernard Cole, Kitty Victoria
Publikováno v:
Cancer Research. 80:P2-16
Background: Randomized studies have demonstrated that adding Cb to P as part of NACT for stage II-III TNBC significantly increases pathologic complete response (pCR) rates, but its optimal dose and schedule are uncertain. Since hematologic toxicities
Autor:
Christine M Emmick, Ashley Stuckey, Marlene Cutitar, Jennifer Gass, Sabrina M Witherby, Robert D. Legare, Mary Anne Fenton, William M. Sikov, Mary L Lopresti, Rochelle Strenger, Jessica J Bian, Theresa A. Graves, David A Edmondson, Sonali V Pandya, Bachir J. Sakr, Donald S Dizon, Adam J. Olszewski
Publikováno v:
Breast Cancer Research and Treatment. 189:93-101
In HER2-positive breast cancer (HER2+ BC), neoadjuvant chemotherapy (NACT) with dual HER2-targeted therapy achieves high pathologic complete response (pCR) rates. Anthracycline-free NACT regimens avoid toxicities associated with anthracyclines, but e
Autor:
Karen L. Smith, Bernard Tawfik, William Fraser Symmans, Kathy D. Miller, Erica L. Mayer, Ingrid A. Mayer, Margaret Block, Angela DeMichele, Shabana Jaynul Dewani, Amye J. Tevaarwerk, Carlos L. Arteaga, Lisa Flaum, Della F. Makower, Craig Mescher, Chirag Jani, Joseph A. Sparano, Lynne I. Wagner, Fengmin Zhao, William M. Sikov, Eve T. Rodler, Ben Ho Park, Kimberly A. Morley, Brian L. Burnette, Antonio C. Wolff, Sofia F. Garcia
Publikováno v:
Journal of Clinical Oncology. 39:3522-3524
Autor:
Andrew Schumacher, William M Sikov, Matthew I Quesenberry, Howard Safran, Humera Khurshid, Kristen M Mitchell, Adam J Olszewski
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0172957 (2017)
BACKGROUND:Informed consent forms (ICFs) for oncology clinical trials have grown increasingly longer and more complex. We evaluated objective understanding of critical components of informed consent among patients enrolling in contemporary trials of
Externí odkaz:
https://doaj.org/article/01cc5eedb1db40f8b3b5e27bf9de8f7d
Autor:
K. Alex Hodge, Maysa M. Abu-Khalaf, Frances Valdes, Rita Murphy, William M. Sikov, Neelima Denduluri, Bryant Dunetz, Christos Hatzis, Mariaelena Pierobon, Kris Awerkamp, Emanuel F. Petricoin, Daniel Zelterman, Monica M. Mita
Publikováno v:
Cancer Research. 81:PS5-28
Background: Three CDK 4/6 inhibitors (inh) are FDA approved in combination with endocrine therapy (ET) for HR+/HER2- metastatic breast cancer (MBC), however, there are no validated predictive markers of response to this class of drugs. Approximately